Search Genes

GET /api/v1/genes/?format=api&page=282
HTTP 200 OK
Allow: GET, HEAD, OPTIONS
Content-Type: application/json
Vary: Accept

{
    "count": 35521,
    "next": "https://panelapp-aus.org/api/v1/genes/?format=api&page=283",
    "previous": "https://panelapp-aus.org/api/v1/genes/?format=api&page=281",
    "results": [
        {
            "gene_data": {
                "alias": [
                    "DAX1",
                    "AHCH"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:7960",
                "gene_name": "nuclear receptor subfamily 0 group B member 1",
                "omim_gene": [
                    "300473"
                ],
                "alias_name": null,
                "gene_symbol": "NR0B1",
                "hgnc_symbol": "NR0B1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "X:30322323-30327715",
                            "ensembl_id": "ENSG00000169297"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "X:30304206-30309598",
                            "ensembl_id": "ENSG00000169297"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1986-01-01"
            },
            "entity_type": "gene",
            "entity_name": "NR0B1",
            "confidence_level": "2",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "7951319",
                "23384712"
            ],
            "evidence": [
                "Expert Review Amber",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "46XY sex reversal 2, dosage-sensitive MIM#300018"
            ],
            "mode_of_inheritance": "X-LINKED: hemizygous mutation in males, monoallelic mutations in females may cause disease (may be less severe, later onset than males)",
            "tags": [
                "SV/CNV"
            ],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "COUP-TFII",
                    "COUPTFB",
                    "SVP40",
                    "NF-E3"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:7976",
                "gene_name": "nuclear receptor subfamily 2 group F member 2",
                "omim_gene": [
                    "107773"
                ],
                "alias_name": null,
                "gene_symbol": "NR2F2",
                "hgnc_symbol": "NR2F2",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "15:96869167-96883492",
                            "ensembl_id": "ENSG00000185551"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "15:96325938-96340263",
                            "ensembl_id": "ENSG00000185551"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1995-03-21"
            },
            "entity_type": "gene",
            "entity_name": "NR2F2",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "29570242",
                "29966037",
                "27363585",
                "29478779"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Expert list",
                "Literature"
            ],
            "phenotypes": [
                "Congenital heart defects, multiple types, 4, MIM# 615779"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "FTZ1",
                    "SF-1",
                    "ELP",
                    "AD4BP",
                    "hSF-1"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:7983",
                "gene_name": "nuclear receptor subfamily 5 group A member 1",
                "omim_gene": [
                    "184757"
                ],
                "alias_name": [
                    "steroidogenic factor 1"
                ],
                "gene_symbol": "NR5A1",
                "hgnc_symbol": "NR5A1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "9:127243516-127269709",
                            "ensembl_id": "ENSG00000136931"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "9:124481236-124507430",
                            "ensembl_id": "ENSG00000136931"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1994-06-07"
            },
            "entity_type": "gene",
            "entity_name": "NR5A1",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "31513305"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "46, XX sex reversal 4 (MIM#617480)",
                "46XY sex reversal 3 (MIM#612965)"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "N-ras"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:7989",
                "gene_name": "NRAS proto-oncogene, GTPase",
                "omim_gene": [
                    "164790"
                ],
                "alias_name": null,
                "gene_symbol": "NRAS",
                "hgnc_symbol": "NRAS",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "1:115247090-115259515",
                            "ensembl_id": "ENSG00000213281"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "1:114704469-114716894",
                            "ensembl_id": "ENSG00000213281"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2001-06-22"
            },
            "entity_type": "gene",
            "entity_name": "NRAS",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "Loss-of-function variants (as defined in pop up message) DO NOT cause this phenotype - please provide details in the comments",
            "publications": [
                "19966803",
                "26467218",
                "28594414"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Victorian Clinical Genetics Services"
            ],
            "phenotypes": [
                "Noonan syndrome 6, MIM# 613224"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "ARA267",
                    "FLJ22263",
                    "KMT3B"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:14234",
                "gene_name": "nuclear receptor binding SET domain protein 1",
                "omim_gene": [
                    "606681"
                ],
                "alias_name": null,
                "gene_symbol": "NSD1",
                "hgnc_symbol": "NSD1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "5:176560026-176727216",
                            "ensembl_id": "ENSG00000165671"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "5:177133025-177300215",
                            "ensembl_id": "ENSG00000165671"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2002-02-25"
            },
            "entity_type": "gene",
            "entity_name": "NSD1",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "29966037"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Victorian Clinical Genetics Services"
            ],
            "phenotypes": [
                "Sotos syndrome 1, MIM# 117550"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "XAP104",
                    "H105e3",
                    "SDR31E1"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:13398",
                "gene_name": "NAD(P) dependent steroid dehydrogenase-like",
                "omim_gene": [
                    "300275"
                ],
                "alias_name": [
                    "short chain dehydrogenase/reductase family 31E, member 1"
                ],
                "gene_symbol": "NSDHL",
                "hgnc_symbol": "NSDHL",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "X:151999511-152038273",
                            "ensembl_id": "ENSG00000147383"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "X:152830967-152869729",
                            "ensembl_id": "ENSG00000147383"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2004-04-30"
            },
            "entity_type": "gene",
            "entity_name": "NSDHL",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "19377476",
                "19842190",
                "21129721",
                "15689440",
                "25900314"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "CK syndrome , MIM#300831"
            ],
            "mode_of_inheritance": "X-LINKED: hemizygous mutation in males, biallelic mutations in females",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "FLJ12660",
                    "IND1",
                    "huInd1"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:20278",
                "gene_name": "nucleotide binding protein like",
                "omim_gene": [
                    "613621"
                ],
                "alias_name": [
                    "iron-sulfur protein required for NADH dehydrogenase"
                ],
                "gene_symbol": "NUBPL",
                "hgnc_symbol": "NUBPL",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "14:31959162-32330430",
                            "ensembl_id": "ENSG00000151413"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "14:31489956-31861224",
                            "ensembl_id": "ENSG00000151413"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2005-01-07"
            },
            "entity_type": "gene",
            "entity_name": "NUBPL",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "29982452"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Mitochondrial complex I deficiency, nuclear type 21 (MIM#618242)"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "NUP84"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:29914",
                "gene_name": "nucleoporin 107",
                "omim_gene": [
                    "607617"
                ],
                "alias_name": null,
                "gene_symbol": "NUP107",
                "hgnc_symbol": "NUP107",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "12:69080514-69136785",
                            "ensembl_id": "ENSG00000111581"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "12:68686734-68745809",
                            "ensembl_id": "ENSG00000111581"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2004-03-19"
            },
            "entity_type": "gene",
            "entity_name": "NUP107",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "28280135",
                "28117080",
                "30179222",
                "25558065"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Victorian Clinical Genetics Services"
            ],
            "phenotypes": [
                "Galloway-Mowat syndrome 7, MIM# 618348"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "KIAA0657"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:29092",
                "gene_name": "obscurin like 1",
                "omim_gene": [
                    "610991"
                ],
                "alias_name": null,
                "gene_symbol": "OBSL1",
                "hgnc_symbol": "OBSL1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "2:220415451-220436581",
                            "ensembl_id": "ENSG00000124006"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "2:219550729-219571859",
                            "ensembl_id": "ENSG00000124006"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2005-10-20"
            },
            "entity_type": "gene",
            "entity_name": "OBSL1",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "21737058",
                "19481195",
                "23018678",
                "19877176"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "3-M syndrome 2 (MIM#612921)"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "PPP1R115"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:8104",
                "gene_name": "occludin",
                "omim_gene": [
                    "602876"
                ],
                "alias_name": [
                    "tight junction protein occludin TM4 minus",
                    "phosphatase 1, regulatory subunit 115"
                ],
                "gene_symbol": "OCLN",
                "hgnc_symbol": "OCLN",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "5:68788119-68853931",
                            "ensembl_id": "ENSG00000197822"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "5:69492292-69558104",
                            "ensembl_id": "ENSG00000197822"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1998-01-20"
            },
            "entity_type": "gene",
            "entity_name": "OCLN",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "20727516",
                "32240828",
                "29192239",
                "28386946"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Pseudo-TORCH syndrome 1 (MIM#251290)"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "OCRL1"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:8108",
                "gene_name": "OCRL, inositol polyphosphate-5-phosphatase",
                "omim_gene": [
                    "300535"
                ],
                "alias_name": null,
                "gene_symbol": "OCRL",
                "hgnc_symbol": "OCRL",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "X:128673826-128726538",
                            "ensembl_id": "ENSG00000122126"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "X:129539849-129592561",
                            "ensembl_id": "ENSG00000122126"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2001-06-22"
            },
            "entity_type": "gene",
            "entity_name": "OCRL",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "33517444"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Victorian Clinical Genetics Services"
            ],
            "phenotypes": [
                "Lowe syndrome, OMIM:309000",
                "Dent disease 2, OMIM:300555"
            ],
            "mode_of_inheritance": "X-LINKED: hemizygous mutation in males, biallelic mutations in females",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "71-7A",
                    "JBTS10"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:2567",
                "gene_name": "OFD1, centriole and centriolar satellite protein",
                "omim_gene": [
                    "300170"
                ],
                "alias_name": null,
                "gene_symbol": "OFD1",
                "hgnc_symbol": "OFD1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "X:13752832-13787480",
                            "ensembl_id": "ENSG00000046651"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "X:13734745-13769353",
                            "ensembl_id": "ENSG00000046651"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1998-10-01"
            },
            "entity_type": "gene",
            "entity_name": "OFD1",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Victorian Clinical Genetics Services",
                "Victorian Clinical Genetics Services",
                "Melbourne Genomics Health Alliance Perinatal Autopsy Flagship"
            ],
            "phenotypes": [
                "Orofaciodigital syndrome I, MIM# 311200",
                "Joubert syndrome 10, MIM# 300804"
            ],
            "mode_of_inheritance": "X-LINKED: hemizygous mutation in males, monoallelic mutations in females may cause disease (may be less severe, later onset than males)",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "OPN1",
                    "ARHGAP41"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:8148",
                "gene_name": "oligophrenin 1",
                "omim_gene": [
                    "300127"
                ],
                "alias_name": null,
                "gene_symbol": "OPHN1",
                "hgnc_symbol": "OPHN1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "X:67262186-67653755",
                            "ensembl_id": "ENSG00000079482"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "X:68042344-68433913",
                            "ensembl_id": "ENSG00000079482"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1998-05-12"
            },
            "entity_type": "gene",
            "entity_name": "OPHN1",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "20528889",
                "9582072",
                "12807966",
                "16221952"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Intellectual developmental disorder, X-linked syndromic, Billuart type (MIM#300486)"
            ],
            "mode_of_inheritance": "X-LINKED: hemizygous mutation in males, biallelic mutations in females",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "HSORC1",
                    "PARC1"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:8487",
                "gene_name": "origin recognition complex subunit 1",
                "omim_gene": [
                    "601902"
                ],
                "alias_name": [
                    "origin recognition complex, subunit 1, S. cerevisiae, homolog-like",
                    "origin recognition complex 1",
                    "replication control protein 1"
                ],
                "gene_symbol": "ORC1",
                "hgnc_symbol": "ORC1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "1:52838501-52870131",
                            "ensembl_id": "ENSG00000085840"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "1:52372829-52404459",
                            "ensembl_id": "ENSG00000085840"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2010-10-12"
            },
            "entity_type": "gene",
            "entity_name": "ORC1",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Meier-Gorlin syndrome 1, MIM# 224690"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "HsORC4",
                    "Orc4p"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:8490",
                "gene_name": "origin recognition complex subunit 4",
                "omim_gene": [
                    "603056"
                ],
                "alias_name": null,
                "gene_symbol": "ORC4",
                "hgnc_symbol": "ORC4",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "2:148687968-148779147",
                            "ensembl_id": "ENSG00000115947"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "2:147930397-148021604",
                            "ensembl_id": "ENSG00000115947"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2010-10-12"
            },
            "entity_type": "gene",
            "entity_name": "ORC4",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Expert list",
                "Victorian Clinical Genetics Services"
            ],
            "phenotypes": [
                "Meier-Gorlin syndrome 2, MIM# 613800",
                "MONDO:0013428"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:17151",
                "gene_name": "origin recognition complex subunit 6",
                "omim_gene": [
                    "607213"
                ],
                "alias_name": null,
                "gene_symbol": "ORC6",
                "hgnc_symbol": "ORC6",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "16:46723555-46732306",
                            "ensembl_id": "ENSG00000091651"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "16:46689643-46698394",
                            "ensembl_id": "ENSG00000091651"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2010-10-12"
            },
            "entity_type": "gene",
            "entity_name": "ORC6",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Expert list",
                "Victorian Clinical Genetics Services"
            ],
            "phenotypes": [
                "Meier-Gorlin syndrome 3, MIM# 613803"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "HSPC019",
                    "GL"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:21652",
                "gene_name": "osteopetrosis associated transmembrane protein 1",
                "omim_gene": [
                    "607649"
                ],
                "alias_name": [
                    "CLCN7 accessory beta subunit"
                ],
                "gene_symbol": "OSTM1",
                "hgnc_symbol": "OSTM1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "6:108362613-108487058",
                            "ensembl_id": "ENSG00000081087"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "6:108041409-108165854",
                            "ensembl_id": "ENSG00000081087"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2003-10-06"
            },
            "entity_type": "gene",
            "entity_name": "OSTM1",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "12627228",
                "15108279",
                "16813530",
                "23772242",
                "32048120"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Osteopetrosis, autosomal recessive 5 (MIM#259720)"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:8522",
                "gene_name": "orthodenticle homeobox 2",
                "omim_gene": [
                    "600037"
                ],
                "alias_name": null,
                "gene_symbol": "OTX2",
                "hgnc_symbol": "OTX2",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "14:57267425-57277197",
                            "ensembl_id": "ENSG00000165588"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "14:56799905-56810479",
                            "ensembl_id": "ENSG00000165588"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1994-02-08"
            },
            "entity_type": "gene",
            "entity_name": "OTX2",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "24859618"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Victorian Clinical Genetics Services"
            ],
            "phenotypes": [
                "Microphthalmia, syndromic 5, MIM# 610125"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "GROS1",
                    "LEPRECAN",
                    "MGC117314"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:19316",
                "gene_name": "prolyl 3-hydroxylase 1",
                "omim_gene": [
                    "610339"
                ],
                "alias_name": [
                    "growth suppressor 1",
                    "procollagen-proline 3-dioxygenase"
                ],
                "gene_symbol": "P3H1",
                "hgnc_symbol": "P3H1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "1:43212006-43232755",
                            "ensembl_id": "ENSG00000117385"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "1:42746335-42767084",
                            "ensembl_id": "ENSG00000117385"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2014-12-12"
            },
            "entity_type": "gene",
            "entity_name": "P3H1",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "27864101",
                "33737016",
                "17277775",
                "19088120"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Osteogenesis imperfecta, type VIII\t610915"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "LIS1",
                    "PAFAH",
                    "NudF"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:8574",
                "gene_name": "platelet activating factor acetylhydrolase 1b regulatory subunit 1",
                "omim_gene": [
                    "601545"
                ],
                "alias_name": [
                    "lissencephaly-1"
                ],
                "gene_symbol": "PAFAH1B1",
                "hgnc_symbol": "PAFAH1B1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "17:2496504-2588909",
                            "ensembl_id": "ENSG00000007168"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "17:2593210-2685615",
                            "ensembl_id": "ENSG00000007168"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1998-04-03"
            },
            "entity_type": "gene",
            "entity_name": "PAFAH1B1",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "11754098",
                "18285425"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Lissencephaly 1, MIM# 607432",
                "Subcortical laminar heterotopia, MIM# 607432",
                "MONDO:0011830"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "hPAK3",
                    "bPAK"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:8592",
                "gene_name": "p21 (RAC1) activated kinase 3",
                "omim_gene": [
                    "300142"
                ],
                "alias_name": null,
                "gene_symbol": "PAK3",
                "hgnc_symbol": "PAK3",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "X:110187513-110470589",
                            "ensembl_id": "ENSG00000077264"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "X:110944285-111227361",
                            "ensembl_id": "ENSG00000077264"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1998-03-25"
            },
            "entity_type": "gene",
            "entity_name": "PAK3",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "24556213",
                "9731525",
                "10946356",
                "12884430",
                "17853471",
                "18523455",
                "32050918",
                "32005903",
                "31943058",
                "31843706",
                "31678216"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Mental retardation, X-linked 30/47, MIM# 300558",
                "Agenesis of the corpus callosum"
            ],
            "mode_of_inheritance": "X-LINKED: hemizygous mutation in males, biallelic mutations in females",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "FLJ21816",
                    "FANCN"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:26144",
                "gene_name": "partner and localizer of BRCA2",
                "omim_gene": [
                    "610355"
                ],
                "alias_name": [
                    "Fanconi anemia, complementation group N"
                ],
                "gene_symbol": "PALB2",
                "hgnc_symbol": "PALB2",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "16:23614488-23652631",
                            "ensembl_id": "ENSG00000083093"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "16:23603160-23641310",
                            "ensembl_id": "ENSG00000083093"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2007-01-15"
            },
            "entity_type": "gene",
            "entity_name": "PALB2",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Victorian Clinical Genetics Services",
                "Victorian Clinical Genetics Services"
            ],
            "phenotypes": [
                "Fanconi anaemia, complementation group N, MIM# 610832"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "ATPSK2"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:8604",
                "gene_name": "3'-phosphoadenosine 5'-phosphosulfate synthase 2",
                "omim_gene": [
                    "603005"
                ],
                "alias_name": [
                    "sulfate adenylyltransferase",
                    "adenylyl-sulfate kinase",
                    "adenosine 5'-phosphosulfate kinase",
                    "bifunctional 3'-phosphoadenosine 5'-phosphosulfate synthase 2"
                ],
                "gene_symbol": "PAPSS2",
                "hgnc_symbol": "PAPSS2",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "10:89419370-89507462",
                            "ensembl_id": "ENSG00000198682"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "10:87659613-87747705",
                            "ensembl_id": "ENSG00000198682"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1999-01-29"
            },
            "entity_type": "gene",
            "entity_name": "PAPSS2",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "22791835",
                "25594860",
                "31461705",
                "23633440",
                "9771708",
                "19474428"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Brachyolmia 4 with mild epiphyseal and metaphyseal changes MIM#612847"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "DAN"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:8609",
                "gene_name": "poly(A)-specific ribonuclease",
                "omim_gene": [
                    "604212"
                ],
                "alias_name": [
                    "deadenylation nuclease"
                ],
                "gene_symbol": "PARN",
                "hgnc_symbol": "PARN",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "16:14529558-14726585",
                            "ensembl_id": "ENSG00000140694"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "16:14435701-14632728",
                            "ensembl_id": "ENSG00000140694"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1998-07-23"
            },
            "entity_type": "gene",
            "entity_name": "PARN",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "25893599",
                "26342108",
                "25848748"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Dyskeratosis congenita, autosomal recessive 6, MIM# 616353"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:8616",
                "gene_name": "paired box 2",
                "omim_gene": [
                    "167409"
                ],
                "alias_name": null,
                "gene_symbol": "PAX2",
                "hgnc_symbol": "PAX2",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "10:102495360-102589698",
                            "ensembl_id": "ENSG00000075891"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "10:100735603-100829941",
                            "ensembl_id": "ENSG00000075891"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1993-06-07"
            },
            "entity_type": "gene",
            "entity_name": "PAX2",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "21654726",
                "24676634",
                "31060108",
                "32203253"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Papillorenal syndrome, MIM# 120330",
                "Renal coloboma syndrome, MONDO:0007352"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "HUP2"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:8617",
                "gene_name": "paired box 3",
                "omim_gene": [
                    "606597"
                ],
                "alias_name": null,
                "gene_symbol": "PAX3",
                "hgnc_symbol": "PAX3",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "2:223064607-223163715",
                            "ensembl_id": "ENSG00000135903"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "2:222199888-222298996",
                            "ensembl_id": "ENSG00000135903"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1992-01-14"
            },
            "entity_type": "gene",
            "entity_name": "PAX3",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Craniofacial-deafness-hand syndrome, MIM#122880",
                "Waardenburg syndrome, type 1, MIM#193500",
                "Waardenburg syndrome, type 3, MIM#148820"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "D11S812E",
                    "AN",
                    "WAGR"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:8620",
                "gene_name": "paired box 6",
                "omim_gene": [
                    "607108"
                ],
                "alias_name": [
                    "aniridia, keratitis"
                ],
                "gene_symbol": "PAX6",
                "hgnc_symbol": "PAX6",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "11:31806340-31839509",
                            "ensembl_id": "ENSG00000007372"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "11:31784779-31818062",
                            "ensembl_id": "ENSG00000007372"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1986-01-01"
            },
            "entity_type": "gene",
            "entity_name": "PAX6",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "31700164",
                "30986449",
                "29930474",
                "22171686",
                "12731001"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Victorian Clinical Genetics Services"
            ],
            "phenotypes": [
                "Microphthalmia",
                "Coloboma, ocular, MIM# 120200"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:8622",
                "gene_name": "paired box 8",
                "omim_gene": [
                    "167415"
                ],
                "alias_name": null,
                "gene_symbol": "PAX8",
                "hgnc_symbol": "PAX8",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "2:113973574-114036527",
                            "ensembl_id": "ENSG00000125618"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "2:113215997-113278950",
                            "ensembl_id": "ENSG00000125618"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1998-11-16"
            },
            "entity_type": "gene",
            "entity_name": "PAX8",
            "confidence_level": "2",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "33434492"
            ],
            "evidence": [
                "Expert Review Amber",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Hypothyroidism, congenital, due to thyroid dysgenesis or hypoplasia, MIM# 218700",
                "Mayer-Rokitansky-Küster-Hauser syndrome (MRKHS)"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "MEL-18"
                ],
                "biotype": null,
                "hgnc_id": "HGNC:12929",
                "gene_name": "polycomb group ring finger 2",
                "omim_gene": [
                    "600346"
                ],
                "alias_name": null,
                "gene_symbol": "PCGF2",
                "hgnc_symbol": "PCGF2",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "17:36890150-36906070",
                            "ensembl_id": "ENSG00000056661"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "17:38733897-38749817",
                            "ensembl_id": "ENSG00000277258"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2005-01-19"
            },
            "entity_type": "gene",
            "entity_name": "PCGF2",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "30526864",
                "30343942"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Turnpenny-Fry syndrome, MIM# 618371"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "KEN",
                    "KIAA0402",
                    "PCN",
                    "PCNTB",
                    "SCKL4"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:16068",
                "gene_name": "pericentrin",
                "omim_gene": [
                    "605925"
                ],
                "alias_name": [
                    "kendrin",
                    "Seckel syndrome 4"
                ],
                "gene_symbol": "PCNT",
                "hgnc_symbol": "PCNT",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "21:47744036-47865682",
                            "ensembl_id": "ENSG00000160299"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "21:46324122-46445769",
                            "ensembl_id": "ENSG00000160299"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2005-11-03"
            },
            "entity_type": "gene",
            "entity_name": "PCNT",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "18174396",
                "12210304",
                "30922925",
                "33460028",
                "32557621",
                "32267100"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Victorian Clinical Genetics Services"
            ],
            "phenotypes": [
                "Microcephalic osteodysplastic primordial dwarfism, type II, MIM# 210720",
                "MONDO:0008872"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "CT",
                    "CTPCT"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:8754",
                "gene_name": "phosphate cytidylyltransferase 1, choline, alpha",
                "omim_gene": [
                    "123695"
                ],
                "alias_name": [
                    "phosphate cytidylyltransferase 1, choline, alpha isoform"
                ],
                "gene_symbol": "PCYT1A",
                "hgnc_symbol": "PCYT1A",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "3:195941093-196014828",
                            "ensembl_id": "ENSG00000161217"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "3:196214222-196287957",
                            "ensembl_id": "ENSG00000161217"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1999-05-05"
            },
            "entity_type": "gene",
            "entity_name": "PCYT1A",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Spondylometaphyseal dysplasia with cone-rod dystrophy, MIM# 608940"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "TFAR15"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:8761",
                "gene_name": "programmed cell death 10",
                "omim_gene": [
                    "609118"
                ],
                "alias_name": null,
                "gene_symbol": "PDCD10",
                "hgnc_symbol": "PDCD10",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "3:167401086-167452727",
                            "ensembl_id": "ENSG00000114209"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "3:167683298-167734939",
                            "ensembl_id": "ENSG00000114209"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1999-12-10"
            },
            "entity_type": "gene",
            "entity_name": "PDCD10",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Cerebral cavernous malformations 3 MIM#603285"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:8783",
                "gene_name": "phosphodiesterase 4D",
                "omim_gene": [
                    "600129"
                ],
                "alias_name": [
                    "phosphodiesterase E3 dunce homolog (Drosophila)"
                ],
                "gene_symbol": "PDE4D",
                "hgnc_symbol": "PDE4D",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "5:58264865-59817947",
                            "ensembl_id": "ENSG00000113448"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "5:58969038-60522120",
                            "ensembl_id": "ENSG00000113448"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1992-06-08"
            },
            "entity_type": "gene",
            "entity_name": "PDE4D",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Acrodysostosis 2, with or without hormone resistance, MIM# 614613"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "JTK12",
                    "CD140b",
                    "PDGFR1"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:8804",
                "gene_name": "platelet derived growth factor receptor beta",
                "omim_gene": [
                    "173410"
                ],
                "alias_name": null,
                "gene_symbol": "PDGFRB",
                "hgnc_symbol": "PDGFRB",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "5:149493400-149535435",
                            "ensembl_id": "ENSG00000113721"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "5:150113837-150155872",
                            "ensembl_id": "ENSG00000113721"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2001-06-22"
            },
            "entity_type": "gene",
            "entity_name": "PDGFRB",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Premature aging syndrome, Penttinen type, MIM# 601812"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:8806",
                "gene_name": "pyruvate dehydrogenase E1 alpha 1 subunit",
                "omim_gene": [
                    "300502"
                ],
                "alias_name": [
                    "pyruvate dehydrogenase E1 component subunit alpha, somatic form, mitochondrial"
                ],
                "gene_symbol": "PDHA1",
                "hgnc_symbol": "PDHA1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "X:19362011-19379823",
                            "ensembl_id": "ENSG00000131828"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "X:19343893-19361705",
                            "ensembl_id": "ENSG00000131828"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1989-06-30"
            },
            "entity_type": "gene",
            "entity_name": "PDHA1",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "26865159",
                "33461977"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Literature"
            ],
            "phenotypes": [
                "Pyruvate dehydrogenase E1-alpha deficiency, MIM# 312170"
            ],
            "mode_of_inheritance": "X-LINKED: hemizygous mutation in males, monoallelic mutations in females may cause disease (may be less severe, later onset than males)",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:8840",
                "gene_name": "peptidase D",
                "omim_gene": [
                    "613230"
                ],
                "alias_name": [
                    "prolidase"
                ],
                "gene_symbol": "PEPD",
                "hgnc_symbol": "PEPD",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "19:33877856-34012700",
                            "ensembl_id": "ENSG00000124299"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "19:33386950-33521794",
                            "ensembl_id": "ENSG00000124299"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1986-01-01"
            },
            "entity_type": "gene",
            "entity_name": "PEPD",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Prolidase deficiency, OMIM #170100"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:8850",
                "gene_name": "peroxisomal biogenesis factor 1",
                "omim_gene": [
                    "602136"
                ],
                "alias_name": null,
                "gene_symbol": "PEX1",
                "hgnc_symbol": "PEX1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "7:92116334-92157845",
                            "ensembl_id": "ENSG00000127980"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "7:92487020-92528531",
                            "ensembl_id": "ENSG00000127980"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1998-01-08"
            },
            "entity_type": "gene",
            "entity_name": "PEX1",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "21031596"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Literature"
            ],
            "phenotypes": [
                "Peroxisome biogenesis disorder 1A (Zellweger) (MIM#214100)"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "RNF69"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:8851",
                "gene_name": "peroxisomal biogenesis factor 10",
                "omim_gene": [
                    "602859"
                ],
                "alias_name": null,
                "gene_symbol": "PEX10",
                "hgnc_symbol": "PEX10",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "1:2336236-2345236",
                            "ensembl_id": "ENSG00000157911"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "1:2403964-2413797",
                            "ensembl_id": "ENSG00000157911"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1998-08-05"
            },
            "entity_type": "gene",
            "entity_name": "PEX10",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "21031596"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Literature"
            ],
            "phenotypes": [
                "Peroxisome biogenesis disorder 6A (Zellweger), MIM# 614870"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:8853",
                "gene_name": "peroxisomal biogenesis factor 11 beta",
                "omim_gene": [
                    "603867"
                ],
                "alias_name": null,
                "gene_symbol": "PEX11B",
                "hgnc_symbol": "PEX11B",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "1:145516252-145523730",
                            "ensembl_id": "ENSG00000131779"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "1:145911350-145918837",
                            "ensembl_id": "ENSG00000131779"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1998-11-11"
            },
            "entity_type": "gene",
            "entity_name": "PEX11B",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "22581968",
                "31724321"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Literature"
            ],
            "phenotypes": [
                "Peroxisome biogenesis disorder 14B, MIM# 614920"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:8854",
                "gene_name": "peroxisomal biogenesis factor 12",
                "omim_gene": [
                    "601758"
                ],
                "alias_name": null,
                "gene_symbol": "PEX12",
                "hgnc_symbol": "PEX12",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "17:33901814-33905882",
                            "ensembl_id": "ENSG00000108733"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "17:35574795-35578863",
                            "ensembl_id": "ENSG00000108733"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1997-05-22"
            },
            "entity_type": "gene",
            "entity_name": "PEX12",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "21031596"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Literature"
            ],
            "phenotypes": [
                "Peroxisome biogenesis disorder 3A (Zellweger), MIM# 614859"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:8855",
                "gene_name": "peroxisomal biogenesis factor 13",
                "omim_gene": [
                    "601789"
                ],
                "alias_name": null,
                "gene_symbol": "PEX13",
                "hgnc_symbol": "PEX13",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "2:61244360-61279125",
                            "ensembl_id": "ENSG00000162928"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "2:61017225-61051990",
                            "ensembl_id": "ENSG00000162928"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1997-06-24"
            },
            "entity_type": "gene",
            "entity_name": "PEX13",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "21031596",
                "19449432"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Literature"
            ],
            "phenotypes": [
                "Peroxisome biogenesis disorder 11A (Zellweger), MIM# 614883"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:8856",
                "gene_name": "peroxisomal biogenesis factor 14",
                "omim_gene": [
                    "601791"
                ],
                "alias_name": null,
                "gene_symbol": "PEX14",
                "hgnc_symbol": "PEX14",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "1:10532345-10690815",
                            "ensembl_id": "ENSG00000142655"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "1:10472288-10630758",
                            "ensembl_id": "ENSG00000142655"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1998-08-21"
            },
            "entity_type": "gene",
            "entity_name": "PEX14",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "21031596",
                "18285423",
                "15146459",
                "30224891",
                "26627464"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Literature"
            ],
            "phenotypes": [
                "Peroxisome biogenesis disorder 13A (Zellweger), MIM# 614887"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:8857",
                "gene_name": "peroxisomal biogenesis factor 16",
                "omim_gene": [
                    "603360"
                ],
                "alias_name": null,
                "gene_symbol": "PEX16",
                "hgnc_symbol": "PEX16",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "11:45931220-45940363",
                            "ensembl_id": "ENSG00000121680"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "11:45909669-45918812",
                            "ensembl_id": "ENSG00000121680"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1999-04-07"
            },
            "entity_type": "gene",
            "entity_name": "PEX16",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "21031596"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Literature"
            ],
            "phenotypes": [
                "Peroxisome biogenesis disorder 8A (Zellweger), MIM# 614876"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "HK33",
                    "D1S2223E",
                    "PMP1",
                    "PMPI",
                    "PXMP1"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:9713",
                "gene_name": "peroxisomal biogenesis factor 19",
                "omim_gene": [
                    "600279"
                ],
                "alias_name": [
                    "housekeeping gene, 33kD"
                ],
                "gene_symbol": "PEX19",
                "hgnc_symbol": "PEX19",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "1:160246602-160256138",
                            "ensembl_id": "ENSG00000162735"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "1:160276812-160286348",
                            "ensembl_id": "ENSG00000162735"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2004-03-19"
            },
            "entity_type": "gene",
            "entity_name": "PEX19",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "21031596"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Literature"
            ],
            "phenotypes": [
                "Peroxisome biogenesis disorder 12A (Zellweger), MIM# 614886"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "PMP35",
                    "PAF-1",
                    "RNF72",
                    "ZWS3"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:9717",
                "gene_name": "peroxisomal biogenesis factor 2",
                "omim_gene": [
                    "170993"
                ],
                "alias_name": [
                    "Zellweger syndrome",
                    "peroxin 2"
                ],
                "gene_symbol": "PEX2",
                "hgnc_symbol": "PEX2",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "8:77892494-77913280",
                            "ensembl_id": "ENSG00000164751"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "8:76980258-77001044",
                            "ensembl_id": "ENSG00000164751"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2010-01-25"
            },
            "entity_type": "gene",
            "entity_name": "PEX2",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "21031596"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Literature"
            ],
            "phenotypes": [
                "Peroxisome biogenesis disorder 5A (Zellweger), MIM# 614866"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "FLJ20695"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:22965",
                "gene_name": "peroxisomal biogenesis factor 26",
                "omim_gene": [
                    "608666"
                ],
                "alias_name": null,
                "gene_symbol": "PEX26",
                "hgnc_symbol": "PEX26",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "22:18560689-18613905",
                            "ensembl_id": "ENSG00000215193"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "22:18077920-18131138",
                            "ensembl_id": "ENSG00000215193"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2003-08-05"
            },
            "entity_type": "gene",
            "entity_name": "PEX26",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "21031596"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Literature"
            ],
            "phenotypes": [
                "Peroxisome biogenesis disorder 7A (Zellweger), MIM# 614872"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:8858",
                "gene_name": "peroxisomal biogenesis factor 3",
                "omim_gene": [
                    "603164"
                ],
                "alias_name": null,
                "gene_symbol": "PEX3",
                "hgnc_symbol": "PEX3",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "6:143771944-143811147",
                            "ensembl_id": "ENSG00000034693"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "6:143450807-143490010",
                            "ensembl_id": "ENSG00000034693"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1998-10-21"
            },
            "entity_type": "gene",
            "entity_name": "PEX3",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "21031596"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Literature"
            ],
            "phenotypes": [
                "Peroxisome biogenesis disorder 10A (Zellweger), MIM# 614882"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "PTS1R"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:9719",
                "gene_name": "peroxisomal biogenesis factor 5",
                "omim_gene": [
                    "600414"
                ],
                "alias_name": [
                    "peroxisomal targeting signal 1 receptor",
                    "peroxisomal import receptor 5"
                ],
                "gene_symbol": "PEX5",
                "hgnc_symbol": "PEX5",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "12:7341281-7371170",
                            "ensembl_id": "ENSG00000139197"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "12:7188685-7218574",
                            "ensembl_id": "ENSG00000139197"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2004-03-19"
            },
            "entity_type": "gene",
            "entity_name": "PEX5",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "21031596"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Literature"
            ],
            "phenotypes": [
                "Peroxisome biogenesis disorder 2A (Zellweger), MIM# 214110"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "PXAAA1",
                    "PAF-2"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:8859",
                "gene_name": "peroxisomal biogenesis factor 6",
                "omim_gene": [
                    "601498"
                ],
                "alias_name": null,
                "gene_symbol": "PEX6",
                "hgnc_symbol": "PEX6",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "6:42931608-42946958",
                            "ensembl_id": "ENSG00000124587"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "6:42963870-42979220",
                            "ensembl_id": "ENSG00000124587"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1997-05-22"
            },
            "entity_type": "gene",
            "entity_name": "PEX6",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "21031596",
                "9877282",
                "26700162"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Literature"
            ],
            "phenotypes": [
                "Peroxisome biogenesis disorder 4A (Zellweger) (MIM#614862)"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "PTS2R",
                    "RD"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:8860",
                "gene_name": "peroxisomal biogenesis factor 7",
                "omim_gene": [
                    "601757"
                ],
                "alias_name": [
                    "Refsum disease"
                ],
                "gene_symbol": "PEX7",
                "hgnc_symbol": "PEX7",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "6:137143717-137235075",
                            "ensembl_id": "ENSG00000112357"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "6:136822564-136913937",
                            "ensembl_id": "ENSG00000112357"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1997-05-22"
            },
            "entity_type": "gene",
            "entity_name": "PEX7",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "11781871",
                "12325024"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Peroxisome biogenesis disorder 9B, OMIM# 614879",
                "Rhizomelic chondrodysplasia punctata, type 1, OMIM# 215100"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "FRAG1",
                    "CWH43-N"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:17893",
                "gene_name": "post-GPI attachment to proteins 2",
                "omim_gene": [
                    "615187"
                ],
                "alias_name": [
                    "FGF receptor activating protein 1",
                    "cell wall biogenesis 43 N-terminal homolog (S. cerevisiae)"
                ],
                "gene_symbol": "PGAP2",
                "hgnc_symbol": "PGAP2",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "11:3818954-3847601",
                            "ensembl_id": "ENSG00000148985"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "11:3797724-3826371",
                            "ensembl_id": "ENSG00000148985"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2009-06-18"
            },
            "entity_type": "gene",
            "entity_name": "PGAP2",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "23561846",
                "23561847",
                "31805394",
                "29119105",
                "27871432"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Hyperphosphatasia with mental retardation syndrome 3, MIM# 614207, MONDO:0013628"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "MGC9753",
                    "CAB2",
                    "PP1498",
                    "PER1"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:23719",
                "gene_name": "post-GPI attachment to proteins 3",
                "omim_gene": [
                    "611801"
                ],
                "alias_name": [
                    "post-GPI attachment to proteins 3"
                ],
                "gene_symbol": "PGAP3",
                "hgnc_symbol": "PGAP3",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "17:37827375-37853050",
                            "ensembl_id": "ENSG00000161395"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "17:39671122-39696797",
                            "ensembl_id": "ENSG00000161395"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2009-06-02"
            },
            "entity_type": "gene",
            "entity_name": "PGAP3",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "24439110",
                "29620724",
                "30345601",
                "30217754"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Hyperphosphatasia with mental retardation syndrome 4, MIM# 615716, MONDO:0014318"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:8905",
                "gene_name": "phosphoglucomutase 1",
                "omim_gene": [
                    "171900"
                ],
                "alias_name": null,
                "gene_symbol": "PGM1",
                "hgnc_symbol": "PGM1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "1:64058947-64125916",
                            "ensembl_id": "ENSG00000079739"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "1:63593276-63660245",
                            "ensembl_id": "ENSG00000079739"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2001-06-22"
            },
            "entity_type": "gene",
            "entity_name": "PGM1",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "24499211",
                "33342467"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Victorian Clinical Genetics Services"
            ],
            "phenotypes": [
                "Congenital disorder of glycosylation, type It 614921"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "KIAA1823",
                    "MGC14797",
                    "CENP-31"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:18145",
                "gene_name": "PHD finger protein 6",
                "omim_gene": [
                    "300414"
                ],
                "alias_name": [
                    "centromere protein 31"
                ],
                "gene_symbol": "PHF6",
                "hgnc_symbol": "PHF6",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "X:133507283-133562820",
                            "ensembl_id": "ENSG00000156531"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "X:134373253-134428791",
                            "ensembl_id": "ENSG00000156531"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2002-02-28"
            },
            "entity_type": "gene",
            "entity_name": "PHF6",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Borjeson-Forssman-Lehmann syndrome, OMIM # 301900"
            ],
            "mode_of_inheritance": "X-LINKED: hemizygous mutation in males, biallelic mutations in females",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "ZNF422",
                    "KIAA1111",
                    "JHDM1F",
                    "KDM7B"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:20672",
                "gene_name": "PHD finger protein 8",
                "omim_gene": [
                    "300560"
                ],
                "alias_name": [
                    "jumonji C domain-containing histone demethylase 1F"
                ],
                "gene_symbol": "PHF8",
                "hgnc_symbol": "PHF8",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "X:53963109-54075391",
                            "ensembl_id": "ENSG00000172943"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "X:53936676-54048958",
                            "ensembl_id": "ENSG00000172943"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2004-04-30"
            },
            "entity_type": "gene",
            "entity_name": "PHF8",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "17661819",
                "17594395",
                "16199551"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Intellectual developmental disorder, X-linked, syndromic, Siderius type, MIM# 300263"
            ],
            "mode_of_inheritance": "X-LINKED: hemizygous mutation in males, biallelic mutations in females",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "SERA",
                    "PGDH",
                    "PDG"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:8923",
                "gene_name": "phosphoglycerate dehydrogenase",
                "omim_gene": [
                    "606879"
                ],
                "alias_name": null,
                "gene_symbol": "PHGDH",
                "hgnc_symbol": "PHGDH",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "1:120202421-120286838",
                            "ensembl_id": "ENSG00000092621"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "1:119648411-119744226",
                            "ensembl_id": "ENSG00000092621"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1999-11-22"
            },
            "entity_type": "gene",
            "entity_name": "PHGDH",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "11895570",
                "11494295"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Expert list"
            ],
            "phenotypes": [
                "Neu-Laxova syndrome 1, MIM# 256520"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "ndrp",
                    "FLJ20705",
                    "DCAF14",
                    "BRWD2"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:15673",
                "gene_name": "pleckstrin homology domain interacting protein",
                "omim_gene": [
                    "612870"
                ],
                "alias_name": [
                    "DDB1 and CUL4 associated factor 14"
                ],
                "gene_symbol": "PHIP",
                "hgnc_symbol": "PHIP",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "6:79645584-79787953",
                            "ensembl_id": "ENSG00000146247"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "6:78935867-79078236",
                            "ensembl_id": "ENSG00000146247"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2001-05-04"
            },
            "entity_type": "gene",
            "entity_name": "PHIP",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "29209020",
                "27900362",
                "23033978"
            ],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp",
                "Expert list"
            ],
            "phenotypes": [
                "Chung-Jansen syndrome, MIM#617991"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "Phox2b",
                    "NBPhox"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:9143",
                "gene_name": "paired like homeobox 2b",
                "omim_gene": [
                    "603851"
                ],
                "alias_name": null,
                "gene_symbol": "PHOX2B",
                "hgnc_symbol": "PHOX2B",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "4:41746099-41750987",
                            "ensembl_id": "ENSG00000109132"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "4:41744082-41748970",
                            "ensembl_id": "ENSG00000109132"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2003-02-14"
            },
            "entity_type": "gene",
            "entity_name": "PHOX2B",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "14608649",
                "15657873",
                "15121777",
                "26063465"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Central hypoventilation syndrome, congenital, 1, with or without Hirschsprung disease, OMIM #209880"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "KIAA0233"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:28993",
                "gene_name": "piezo type mechanosensitive ion channel component 1",
                "omim_gene": [
                    "611184"
                ],
                "alias_name": null,
                "gene_symbol": "PIEZO1",
                "hgnc_symbol": "PIEZO1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "16:88781751-88851619",
                            "ensembl_id": "ENSG00000103335"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "16:88715343-88785211",
                            "ensembl_id": "ENSG00000103335"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2011-08-31"
            },
            "entity_type": "gene",
            "entity_name": "PIEZO1",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "23695678",
                "30712880",
                "26333996",
                "28425981",
                "23479567"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Dehydrated hereditary stomatocytosis with or without pseudohyperkalemia and/or perinatal edema, OMIM #194380",
                "Lymphatic malformation 6, OMIM #616843"
            ],
            "mode_of_inheritance": "BOTH monoallelic and biallelic, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "FLJ23403",
                    "FLJ23144",
                    "HsT748",
                    "HsT771",
                    "FLJ34907"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:26270",
                "gene_name": "piezo type mechanosensitive ion channel component 2",
                "omim_gene": [
                    "613629"
                ],
                "alias_name": null,
                "gene_symbol": "PIEZO2",
                "hgnc_symbol": "PIEZO2",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "18:10666480-11148587",
                            "ensembl_id": "ENSG00000154864"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "18:10666483-11148762",
                            "ensembl_id": "ENSG00000154864"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2011-08-31"
            },
            "entity_type": "gene",
            "entity_name": "PIEZO2",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "24726473",
                "30941898"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Marden-Walker syndrome, MIM# 248700",
                "Arthrogryposis, distal, type 3, MIM# 114300"
            ],
            "mode_of_inheritance": "BOTH monoallelic and biallelic, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "GPI3"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:8957",
                "gene_name": "phosphatidylinositol glycan anchor biosynthesis class A",
                "omim_gene": [
                    "311770"
                ],
                "alias_name": [
                    "paroxysmal nocturnal hemoglobinuria",
                    "phosphatidylinositol N-acetylglucosaminyltransferase"
                ],
                "gene_symbol": "PIGA",
                "hgnc_symbol": "PIGA",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "X:15337573-15353676",
                            "ensembl_id": "ENSG00000165195"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "X:15319451-15335580",
                            "ensembl_id": "ENSG00000165195"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1993-10-28"
            },
            "entity_type": "gene",
            "entity_name": "PIGA",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "24706016",
                "24259184",
                "29159939"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Multiple congenital anomalies-hypotonia-seizures syndrome 2, MIM#300868"
            ],
            "mode_of_inheritance": "X-LINKED: hemizygous mutation in males, biallelic mutations in females",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:8966",
                "gene_name": "phosphatidylinositol glycan anchor biosynthesis class L",
                "omim_gene": [
                    "605947"
                ],
                "alias_name": [
                    "N-acetylglucosaminylphosphatidylinositol deacetylase"
                ],
                "gene_symbol": "PIGL",
                "hgnc_symbol": "PIGL",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "17:16120505-16252115",
                            "ensembl_id": "ENSG00000108474"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "17:16217191-16351797",
                            "ensembl_id": "ENSG00000108474"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1999-04-15"
            },
            "entity_type": "gene",
            "entity_name": "PIGL",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "22444671",
                "31535386",
                "30023290",
                "29473937",
                "28371479",
                "25706356"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "CHIME syndrome, MIM# 280000, MONDO:0010221"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [
                "SV/CNV"
            ],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "DKFZp434M222",
                    "FLJ00135"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:23215",
                "gene_name": "phosphatidylinositol glycan anchor biosynthesis class O",
                "omim_gene": [
                    "614730"
                ],
                "alias_name": null,
                "gene_symbol": "PIGO",
                "hgnc_symbol": "PIGO",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "9:35088685-35096591",
                            "ensembl_id": "ENSG00000165282"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "9:35088688-35096601",
                            "ensembl_id": "ENSG00000165282"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2003-10-14"
            },
            "entity_type": "gene",
            "entity_name": "PIGO",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "22683086",
                "31698102",
                "28900819",
                "28545593",
                "28337824"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Hyperphosphatasia with mental retardation syndrome 2, MIM# 614749, MONDO:0013882"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:14938",
                "gene_name": "phosphatidylinositol glycan anchor biosynthesis class T",
                "omim_gene": [
                    "610272"
                ],
                "alias_name": [
                    "GPI transamidase subunit"
                ],
                "gene_symbol": "PIGT",
                "hgnc_symbol": "PIGT",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "20:44044717-44054884",
                            "ensembl_id": "ENSG00000124155"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "20:45416067-45456934",
                            "ensembl_id": "ENSG00000124155"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2001-03-27"
            },
            "entity_type": "gene",
            "entity_name": "PIGT",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "30976099",
                "25943031",
                "24906948",
                "24906948",
                "24906948",
                "28728837",
                "28728837",
                "28728837"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Multiple congenital anomalies-hypotonia-seizures syndrome 3, MIM# 615398, MONDO:0014165"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "FLJ20477"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:26031",
                "gene_name": "phosphatidylinositol glycan anchor biosynthesis class V",
                "omim_gene": [
                    "610274"
                ],
                "alias_name": [
                    "GPI mannosyltransferase 2",
                    "dol-P-Man dependent GPI mannosyltransferase"
                ],
                "gene_symbol": "PIGV",
                "hgnc_symbol": "PIGV",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "1:27113963-27124889",
                            "ensembl_id": "ENSG00000060642"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "1:26787472-26798398",
                            "ensembl_id": "ENSG00000060642"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2005-01-10"
            },
            "entity_type": "gene",
            "entity_name": "PIGV",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "20802478",
                "22315194",
                "28817240",
                "24129430"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Hyperphosphatasia with mental retardation syndrome 1, MIM# 239300, MONDO:0009398"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "PI3K"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:8975",
                "gene_name": "phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha",
                "omim_gene": [
                    "171834"
                ],
                "alias_name": null,
                "gene_symbol": "PIK3CA",
                "hgnc_symbol": "PIK3CA",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "3:178865902-178957881",
                            "ensembl_id": "ENSG00000121879"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "3:179148114-179240093",
                            "ensembl_id": "ENSG00000121879"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1994-07-15"
            },
            "entity_type": "gene",
            "entity_name": "PIK3CA",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "30712880",
                "28425981",
                "23754335"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Expert list"
            ],
            "phenotypes": [
                "Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 2, MIM# 615937"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "GRB1",
                    "p85-ALPHA",
                    "p85"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:8979",
                "gene_name": "phosphoinositide-3-kinase regulatory subunit 1",
                "omim_gene": [
                    "171833"
                ],
                "alias_name": [
                    "phosphoinositide-3-kinase regulatory subunit alpha"
                ],
                "gene_symbol": "PIK3R1",
                "hgnc_symbol": "PIK3R1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "5:67511548-67597649",
                            "ensembl_id": "ENSG00000145675"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "5:68215720-68301821",
                            "ensembl_id": "ENSG00000145675"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1992-12-08"
            },
            "entity_type": "gene",
            "entity_name": "PIK3R1",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "SHORT syndrome, MIM#269880"
            ],
            "mode_of_inheritance": "BOTH monoallelic and biallelic, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "P85B",
                    "p85"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:8980",
                "gene_name": "phosphoinositide-3-kinase regulatory subunit 2",
                "omim_gene": [
                    "603157"
                ],
                "alias_name": [
                    "phosphoinositide-3-kinase regulatory subunit beta"
                ],
                "gene_symbol": "PIK3R2",
                "hgnc_symbol": "PIK3R2",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "19:18263928-18281350",
                            "ensembl_id": "ENSG00000105647"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "19:18153118-18170540",
                            "ensembl_id": "ENSG00000105647"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1992-12-08"
            },
            "entity_type": "gene",
            "entity_name": "PIK3R2",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "28425981",
                "22729224",
                "23745724",
                "33604570"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 1, MIM# 603387"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "IGDS",
                    "RS",
                    "Brx1",
                    "Otlx2",
                    "ARP1"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:9005",
                "gene_name": "paired like homeodomain 2",
                "omim_gene": [
                    "601542"
                ],
                "alias_name": null,
                "gene_symbol": "PITX2",
                "hgnc_symbol": "PITX2",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "4:111538579-111563279",
                            "ensembl_id": "ENSG00000164093"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "4:110617423-110642123",
                            "ensembl_id": "ENSG00000164093"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1992-10-05"
            },
            "entity_type": "gene",
            "entity_name": "PITX2",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "12015277"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Anterior segment dysgenesis 4, OMIM #137600",
                "Axenfeld-Rieger syndrome, type 1, OMIM #180500"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:9006",
                "gene_name": "paired like homeodomain 3",
                "omim_gene": [
                    "602669"
                ],
                "alias_name": null,
                "gene_symbol": "PITX3",
                "hgnc_symbol": "PITX3",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "10:103989943-104001231",
                            "ensembl_id": "ENSG00000107859"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "10:102230186-102241474",
                            "ensembl_id": "ENSG00000107859"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1998-06-04"
            },
            "entity_type": "gene",
            "entity_name": "PITX3",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "29405783"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Victorian Clinical Genetics Services"
            ],
            "phenotypes": [
                "Anterior segment dysgenesis 1, multiple subtypes, MIM# 107250",
                "Cataract 11, multiple types, MIM# 610623",
                "Microphthalmia"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "PBP",
                    "Pc-1",
                    "TRPP1"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:9008",
                "gene_name": "polycystin 1, transient receptor potential channel interacting",
                "omim_gene": [
                    "601313"
                ],
                "alias_name": [
                    "polycystin 1",
                    "transient receptor potential cation channel, subfamily P, member 1"
                ],
                "gene_symbol": "PKD1",
                "hgnc_symbol": "PKD1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "16:2138711-2185899",
                            "ensembl_id": "ENSG00000008710"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "16:2088710-2135898",
                            "ensembl_id": "ENSG00000008710"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2001-06-22"
            },
            "entity_type": "gene",
            "entity_name": "PKD1",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "23624871",
                "20558538",
                "30631912",
                "26139440"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Polycystic kidney disease 1, OMIM #173900"
            ],
            "mode_of_inheritance": "BOTH monoallelic and biallelic (but BIALLELIC mutations cause a more SEVERE disease form), autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "PRO19563"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:18053",
                "gene_name": "polycystin 1 like 1, transient receptor potential channel interacting",
                "omim_gene": [
                    "609721"
                ],
                "alias_name": [
                    "polycystin-1L1"
                ],
                "gene_symbol": "PKD1L1",
                "hgnc_symbol": "PKD1L1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "7:47814250-47988088",
                            "ensembl_id": "ENSG00000158683"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "7:47774652-47948491",
                            "ensembl_id": "ENSG00000158683"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2002-03-21"
            },
            "entity_type": "gene",
            "entity_name": "PKD1L1",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "31026592",
                "27616478",
                "30664273",
                "20080492"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Victorian Clinical Genetics Services"
            ],
            "phenotypes": [
                "Heterotaxy, visceral, 8, autosomal (MIM#617205)"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "PKD4",
                    "PC2",
                    "Pc-2",
                    "TRPP2"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:9009",
                "gene_name": "polycystin 2, transient receptor potential cation channel",
                "omim_gene": [
                    "173910"
                ],
                "alias_name": [
                    "transient receptor potential cation channel, subfamily P, member 2"
                ],
                "gene_symbol": "PKD2",
                "hgnc_symbol": "PKD2",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "4:88928820-88998929",
                            "ensembl_id": "ENSG00000118762"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "4:88007668-88077777",
                            "ensembl_id": "ENSG00000118762"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1988-08-07"
            },
            "entity_type": "gene",
            "entity_name": "PKD2",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "26139440"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Polycystic kidney disease 2, OMIM #613095"
            ],
            "mode_of_inheritance": "BOTH monoallelic and biallelic (but BIALLELIC mutations cause a more SEVERE disease form), autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "ARPKD",
                    "FCYT",
                    "FPC"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:9016",
                "gene_name": "PKHD1, fibrocystin/polyductin",
                "omim_gene": [
                    "606702"
                ],
                "alias_name": [
                    "tigmin",
                    "polyductin",
                    "fibrocystin",
                    "fibrocystin/polyductin complex"
                ],
                "gene_symbol": "PKHD1",
                "hgnc_symbol": "PKHD1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "6:51480098-51952423",
                            "ensembl_id": "ENSG00000170927"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "6:51615300-52087625",
                            "ensembl_id": "ENSG00000170927"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1994-12-15"
            },
            "entity_type": "gene",
            "entity_name": "PKHD1",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Expert Review"
            ],
            "phenotypes": [
                "Polycystic kidney disease 4, with or without hepatic disease, MIM# 263200"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:9020",
                "gene_name": "pyruvate kinase L/R",
                "omim_gene": [
                    "609712"
                ],
                "alias_name": null,
                "gene_symbol": "PKLR",
                "hgnc_symbol": "PKLR",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "1:155259630-155271225",
                            "ensembl_id": "ENSG00000143627"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "1:155289839-155301434",
                            "ensembl_id": "ENSG00000143627"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2001-06-22"
            },
            "entity_type": "gene",
            "entity_name": "PKLR",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "29549173",
                "8285758",
                "10923218"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Expert list"
            ],
            "phenotypes": [
                "Pyruvate kinase deficiency 266200"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "Sak"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:11397",
                "gene_name": "polo like kinase 4",
                "omim_gene": [
                    "605031"
                ],
                "alias_name": null,
                "gene_symbol": "PLK4",
                "hgnc_symbol": "PLK4",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "4:128802016-128820350",
                            "ensembl_id": "ENSG00000142731"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "4:127880861-127899195",
                            "ensembl_id": "ENSG00000142731"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2004-01-28"
            },
            "entity_type": "gene",
            "entity_name": "PLK4",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "25344692",
                "25320347",
                "27650967",
                "33756487"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Microcephaly and chorioretinopathy, autosomal recessive, 2, OMIM #616171"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "LH1"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:9081",
                "gene_name": "procollagen-lysine,2-oxoglutarate 5-dioxygenase 1",
                "omim_gene": [
                    "153454"
                ],
                "alias_name": [
                    "lysyl hydroxlase 1"
                ],
                "gene_symbol": "PLOD1",
                "hgnc_symbol": "PLOD1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "1:11994262-12035595",
                            "ensembl_id": "ENSG00000083444"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "1:11934205-11975538",
                            "ensembl_id": "ENSG00000083444"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2004-12-14"
            },
            "entity_type": "gene",
            "entity_name": "PLOD1",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "15666309",
                "20301635",
                "28757364"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Ehlers-Danlos syndrome, kyphoscoliotic type, 1, OMIM #225400"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "LH2"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:9082",
                "gene_name": "procollagen-lysine,2-oxoglutarate 5-dioxygenase 2",
                "omim_gene": [
                    "601865"
                ],
                "alias_name": [
                    "lysyl hydroxlase 2",
                    "procollagen-lysine 5-dioxygenase"
                ],
                "gene_symbol": "PLOD2",
                "hgnc_symbol": "PLOD2",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "3:145787227-145881440",
                            "ensembl_id": "ENSG00000152952"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "3:146069440-146163653",
                            "ensembl_id": "ENSG00000152952"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1996-12-18"
            },
            "entity_type": "gene",
            "entity_name": "PLOD2",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "22689593",
                "12881513",
                "33664768",
                "33778323",
                "29178448"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Bruck syndrome 2 , OMIM #609220"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "CDGS",
                    "CDG1a",
                    "PMI",
                    "PMI1"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:9115",
                "gene_name": "phosphomannomutase 2",
                "omim_gene": [
                    "601785"
                ],
                "alias_name": [
                    "phosphomannose isomerase 1",
                    "mannose-6-phosphate isomerase"
                ],
                "gene_symbol": "PMM2",
                "hgnc_symbol": "PMM2",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "16:8882680-8943188",
                            "ensembl_id": "ENSG00000140650"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "16:8788823-8849331",
                            "ensembl_id": "ENSG00000140650"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1997-05-22"
            },
            "entity_type": "gene",
            "entity_name": "PMM2",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "21541725"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Congenital disorder of glycosylation, type Ia , MIM#212065"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "PNK"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:9154",
                "gene_name": "polynucleotide kinase 3'-phosphatase",
                "omim_gene": [
                    "605610"
                ],
                "alias_name": null,
                "gene_symbol": "PNKP",
                "hgnc_symbol": "PNKP",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "19:50364461-50371166",
                            "ensembl_id": "ENSG00000039650"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "19:49859882-49878351",
                            "ensembl_id": "ENSG00000039650"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1999-12-22"
            },
            "entity_type": "gene",
            "entity_name": "PNKP",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "23224214",
                "20118933"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Microcephaly, seizures, and developmental delay, MIM#613402"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "DKFZP434C245"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:24488",
                "gene_name": "POC1 centriolar protein A",
                "omim_gene": [
                    "614783"
                ],
                "alias_name": null,
                "gene_symbol": "POC1A",
                "hgnc_symbol": "POC1A",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "3:52109269-52188706",
                            "ensembl_id": "ENSG00000164087"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "3:52075253-52154690",
                            "ensembl_id": "ENSG00000164087"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2010-03-26"
            },
            "entity_type": "gene",
            "entity_name": "POC1A",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Short stature, onychodysplasia, facial dysmorphism, and hypotrichosis, MIM#614813"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "KIAA0461",
                    "ZNF635m",
                    "ZNF280E"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:18801",
                "gene_name": "pogo transposable element derived with ZNF domain",
                "omim_gene": [
                    "614787"
                ],
                "alias_name": [
                    "zinc finger protein 280E",
                    "putative protein product of Nbla00003"
                ],
                "gene_symbol": "POGZ",
                "hgnc_symbol": "POGZ",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "1:151375200-151431941",
                            "ensembl_id": "ENSG00000143442"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "1:151402724-151459465",
                            "ensembl_id": "ENSG00000143442"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2002-08-29"
            },
            "entity_type": "gene",
            "entity_name": "POGZ",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "33098347",
                "31782611",
                "26942287"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "White-Sutton syndrome, MIM# 616364",
                "MONDO:0014606"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "RPA40",
                    "RPA39",
                    "RPA5",
                    "RPAC1"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:20194",
                "gene_name": "RNA polymerase I subunit C",
                "omim_gene": [
                    "610060"
                ],
                "alias_name": null,
                "gene_symbol": "POLR1C",
                "hgnc_symbol": "POLR1C",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "6:43477440-43497323",
                            "ensembl_id": "ENSG00000171453"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "6:43509702-43529585",
                            "ensembl_id": "ENSG00000171453"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2003-04-01"
            },
            "entity_type": "gene",
            "entity_name": "POLR1C",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "26151409"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Expert list"
            ],
            "phenotypes": [
                "Treacher Collins syndrome 3, MIM# 248390"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "RPAC2",
                    "RPA16",
                    "RPO1-3",
                    "RPA9",
                    "MGC9850"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:20422",
                "gene_name": "RNA polymerase I subunit D",
                "omim_gene": [
                    "613715"
                ],
                "alias_name": null,
                "gene_symbol": "POLR1D",
                "hgnc_symbol": "POLR1D",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "13:28194903-28241548",
                            "ensembl_id": "ENSG00000186184"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "13:27620742-27744237",
                            "ensembl_id": "ENSG00000186184"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2003-04-01"
            },
            "entity_type": "gene",
            "entity_name": "POLR1D",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "21131976",
                "24603435",
                "27448281",
                "25790162"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Treacher Collins syndrome 2, MIM# 613717"
            ],
            "mode_of_inheritance": "BOTH monoallelic and biallelic, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "RPC1",
                    "RPC155",
                    "hRPC155"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:30074",
                "gene_name": "RNA polymerase III subunit A",
                "omim_gene": [
                    "614258"
                ],
                "alias_name": null,
                "gene_symbol": "POLR3A",
                "hgnc_symbol": "POLR3A",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "10:79734907-79789303",
                            "ensembl_id": "ENSG00000148606"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "10:77969251-78029545",
                            "ensembl_id": "ENSG00000148606"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2004-09-16"
            },
            "entity_type": "gene",
            "entity_name": "POLR3A",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "30323018"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Wiedemann-Rautenstrauch syndrome, MIM# 264090"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "RPC2",
                    "FLJ10388"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:30348",
                "gene_name": "RNA polymerase III subunit B",
                "omim_gene": [
                    "614366"
                ],
                "alias_name": null,
                "gene_symbol": "POLR3B",
                "hgnc_symbol": "POLR3B",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "12:106751436-106903976",
                            "ensembl_id": "ENSG00000013503"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "12:106357658-106510198",
                            "ensembl_id": "ENSG00000013503"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2004-04-21"
            },
            "entity_type": "gene",
            "entity_name": "POLR3B",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Leukodystrophy, hypomyelinating, 8, with or without oligodontia and/or hypogonadotropic hypogonadism, OMIM:614381"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "FLJ20277",
                    "MGAT1.2",
                    "LGMD2O"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:19139",
                "gene_name": "protein O-linked mannose N-acetylglucosaminyltransferase 1 (beta 1,2-)",
                "omim_gene": [
                    "606822"
                ],
                "alias_name": [
                    "protein O-mannose beta-1,2-N-acetylglucosaminyltransferase"
                ],
                "gene_symbol": "POMGNT1",
                "hgnc_symbol": "POMGNT1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "1:46654354-46685977",
                            "ensembl_id": "ENSG00000085998"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "1:46188682-46220305",
                            "ensembl_id": "ENSG00000085998"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2005-06-02"
            },
            "entity_type": "gene",
            "entity_name": "POMGNT1",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Victorian Clinical Genetics Services"
            ],
            "phenotypes": [
                "Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A3, 253280"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "FLJ14566",
                    "AGO61"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:25902",
                "gene_name": "protein O-linked mannose N-acetylglucosaminyltransferase 2 (beta 1,4-)",
                "omim_gene": [
                    "614828"
                ],
                "alias_name": null,
                "gene_symbol": "POMGNT2",
                "hgnc_symbol": "POMGNT2",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "3:43120724-43147568",
                            "ensembl_id": "ENSG00000144647"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "3:43079232-43106076",
                            "ensembl_id": "ENSG00000144647"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2013-08-22"
            },
            "entity_type": "gene",
            "entity_name": "POMGNT2",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Victorian Clinical Genetics Services"
            ],
            "phenotypes": [
                "Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies, type A, 8, MIM# 614830"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "FLJ23356",
                    "SgK196"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:26267",
                "gene_name": "protein-O-mannose kinase",
                "omim_gene": [
                    "615247"
                ],
                "alias_name": null,
                "gene_symbol": "POMK",
                "hgnc_symbol": "POMK",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "8:42948658-42978577",
                            "ensembl_id": "ENSG00000185900"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "8:43093506-43123434",
                            "ensembl_id": "ENSG00000185900"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2013-08-22"
            },
            "entity_type": "gene",
            "entity_name": "POMK",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "24556084",
                "24925318",
                "23519211"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A 615249"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "LGMD2K"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:9202",
                "gene_name": "protein O-mannosyltransferase 1",
                "omim_gene": [
                    "607423"
                ],
                "alias_name": [
                    "dolichyl-phosphate-mannose-protein mannosyltransferase"
                ],
                "gene_symbol": "POMT1",
                "hgnc_symbol": "POMT1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "9:134378289-134399193",
                            "ensembl_id": "ENSG00000130714"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "9:131502902-131523806",
                            "ensembl_id": "ENSG00000130714"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1999-06-25"
            },
            "entity_type": "gene",
            "entity_name": "POMT1",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "17878207",
                "19299310"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Victorian Clinical Genetics Services"
            ],
            "phenotypes": [
                "Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 1 236670",
                "Walker-Walburg syndrome"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "LGMD2N"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:19743",
                "gene_name": "protein O-mannosyltransferase 2",
                "omim_gene": [
                    "607439"
                ],
                "alias_name": [
                    "Dolichyl-phosphate-mannose--protein mannosyltransferase"
                ],
                "gene_symbol": "POMT2",
                "hgnc_symbol": "POMT2",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "14:77741299-77787227",
                            "ensembl_id": "ENSG00000009830"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "14:77274956-77320884",
                            "ensembl_id": "ENSG00000009830"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2003-01-17"
            },
            "entity_type": "gene",
            "entity_name": "POMT2",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "15894594",
                "17878207"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Victorian Clinical Genetics Services"
            ],
            "phenotypes": [
                "Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 2 613150"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "CYPOR",
                    "FLJ26468"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:9208",
                "gene_name": "cytochrome p450 oxidoreductase",
                "omim_gene": [
                    "124015"
                ],
                "alias_name": null,
                "gene_symbol": "POR",
                "hgnc_symbol": "POR",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "7:75528518-75616173",
                            "ensembl_id": "ENSG00000127948"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "7:75899200-75986855",
                            "ensembl_id": "ENSG00000127948"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1989-06-30"
            },
            "entity_type": "gene",
            "entity_name": "POR",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Victorian Clinical Genetics Services"
            ],
            "phenotypes": [
                "Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis 201750",
                "Disordered steroidogenesis due to cytochrome P450 oxidoreductase 613571"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "MG61",
                    "PORC",
                    "PPN",
                    "por"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:17652",
                "gene_name": "porcupine O-acyltransferase",
                "omim_gene": [
                    "300651"
                ],
                "alias_name": null,
                "gene_symbol": "PORCN",
                "hgnc_symbol": "PORCN",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "X:48367350-48379202",
                            "ensembl_id": "ENSG00000102312"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "X:48508962-48520814",
                            "ensembl_id": "ENSG00000102312"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2004-05-12"
            },
            "entity_type": "gene",
            "entity_name": "PORCN",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "25026905"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Victorian Clinical Genetics Services"
            ],
            "phenotypes": [
                "Focal dermal hypoplasia, MIM# 305600"
            ],
            "mode_of_inheritance": "X-LINKED: hemizygous mutation in males, monoallelic mutations in females may cause disease (may be less severe, later onset than males)",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "GHF-1",
                    "POU1F1a"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:9210",
                "gene_name": "POU class 1 homeobox 1",
                "omim_gene": [
                    "173110"
                ],
                "alias_name": [
                    "growth hormone factor 1"
                ],
                "gene_symbol": "POU1F1",
                "hgnc_symbol": "POU1F1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "3:87308554-87325737",
                            "ensembl_id": "ENSG00000064835"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "3:87259404-87276587",
                            "ensembl_id": "ENSG00000064835"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1993-01-12"
            },
            "entity_type": "gene",
            "entity_name": "POU1F1",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "7593413"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Pituitary hormone deficiency, combined, 1, MIM# 613038"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "CYPB",
                    "OI9"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:9255",
                "gene_name": "peptidylprolyl isomerase B",
                "omim_gene": [
                    "123841"
                ],
                "alias_name": [
                    "cyclophilin B"
                ],
                "gene_symbol": "PPIB",
                "hgnc_symbol": "PPIB",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "15:64448011-64455404",
                            "ensembl_id": "ENSG00000166794"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "15:64155812-64163205",
                            "ensembl_id": "ENSG00000166794"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1991-11-25"
            },
            "entity_type": "gene",
            "entity_name": "PPIB",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "19781681",
                "32392875"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Osteogenesis imperfecta, type IX, MIM# 259440"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "PP1B",
                    "PP-1B",
                    "PP1beta"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:9282",
                "gene_name": "protein phosphatase 1 catalytic subunit beta",
                "omim_gene": [
                    "600590"
                ],
                "alias_name": null,
                "gene_symbol": "PPP1CB",
                "hgnc_symbol": "PPP1CB",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "2:28974506-29025806",
                            "ensembl_id": "ENSG00000213639"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "2:28751640-28802940",
                            "ensembl_id": "ENSG00000213639"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1993-01-22"
            },
            "entity_type": "gene",
            "entity_name": "PPP1CB",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "32476286",
                "28211982",
                "27264673",
                "27681385",
                "27868344"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Literature",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Noonan syndrome-like disorder with loose anlagen hair 2, OMIM # 617506"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "PR65A",
                    "PP2A-Aalpha",
                    "PP2AA"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:9302",
                "gene_name": "protein phosphatase 2 scaffold subunit Aalpha",
                "omim_gene": [
                    "605983"
                ],
                "alias_name": [
                    "protein phosphatase 2A, regulatory subunit A, alpha isoform",
                    "protein phosphatase 2, 65kDa regulatory subunit A",
                    "protein phosphatase 2A structural subunit A, alpha isoform"
                ],
                "gene_symbol": "PPP2R1A",
                "hgnc_symbol": "PPP2R1A",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "19:52693292-52730687",
                            "ensembl_id": "ENSG00000105568"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "19:52190039-52229533",
                            "ensembl_id": "ENSG00000105568"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1993-01-25"
            },
            "entity_type": "gene",
            "entity_name": "PPP2R1A",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "Other",
            "publications": [
                "33106617",
                "26168268"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Literature",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Mental retardation, autosomal dominant 36, MIM#616362",
                "Microcephaly-corpus callosum hypoplasia-intellectual disability-facial dysmorphism syndrome, MONDO:0014605"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "B56D",
                    "B56delta"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:9312",
                "gene_name": "protein phosphatase 2 regulatory subunit B'delta",
                "omim_gene": [
                    "601646"
                ],
                "alias_name": null,
                "gene_symbol": "PPP2R5D",
                "hgnc_symbol": "PPP2R5D",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "6:42952237-42980080",
                            "ensembl_id": "ENSG00000112640"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "6:42984499-43012342",
                            "ensembl_id": "ENSG00000112640"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1996-05-08"
            },
            "entity_type": "gene",
            "entity_name": "PPP2R5D",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "32074998",
                "26168268"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Houge-Janssens syndrome 1, MIM#616355"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:9330",
                "gene_name": "polyglutamine binding protein 1",
                "omim_gene": [
                    "300463"
                ],
                "alias_name": null,
                "gene_symbol": "PQBP1",
                "hgnc_symbol": "PQBP1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "X:48755195-48760420",
                            "ensembl_id": "ENSG00000102103"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "X:48897912-48903143",
                            "ensembl_id": "ENSG00000102103"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1999-01-12"
            },
            "entity_type": "gene",
            "entity_name": "PQBP1",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "31840929",
                "14634649",
                "20410308"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Renpenning syndrome, MIM#309500"
            ],
            "mode_of_inheritance": "X-LINKED: hemizygous mutation in males, biallelic mutations in females",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "JCAP",
                    "SZP",
                    "MSF",
                    "HAPO",
                    "bG174L6.2",
                    "FLJ32635"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:9364",
                "gene_name": "proteoglycan 4",
                "omim_gene": [
                    "604283"
                ],
                "alias_name": [
                    "lubricin",
                    "megakaryocyte stimulating factor",
                    "articular superficial zone protein",
                    "Jacobs camptodactyly-arthropathy-pericarditis syndrome",
                    "camptodactyly, arthropathy, coxa vara, pericarditis syndrome",
                    "bG174L6.2 (MSF: megakaryocyte stimulating factor )"
                ],
                "gene_symbol": "PRG4",
                "hgnc_symbol": "PRG4",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "1:186265405-186283694",
                            "ensembl_id": "ENSG00000116690"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "1:186296279-186314562",
                            "ensembl_id": "ENSG00000116690"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2000-07-31"
            },
            "entity_type": "gene",
            "entity_name": "PRG4",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "10545950",
                "29397575"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Camptodactyly-arthropathy-coxa vara-pericarditis syndrome 208250"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        }
    ]
}